tiprankstipranks
Trending News
More News >
HeraMED Ltd. (AU:HMD)
:HMD

HeraMED Ltd. (HMD) AI Stock Analysis

Compare
3 Followers

Top Page

AU

HeraMED Ltd.

(Frankfurt:HMD)

Rating:45Neutral
Price Target:
HeraMED Ltd. receives a low overall score due to significant financial performance challenges. Declining revenues, negative profit margins, and reliance on external financing are major concerns. Technical analysis shows neutral to slightly positive momentum, but valuation metrics are unfavorable due to negative earnings. The absence of recent earnings call data or corporate events leaves financial and operational issues as the primary focus.

HeraMED Ltd. (HMD) vs. iShares MSCI Australia ETF (EWA)

HeraMED Ltd. Business Overview & Revenue Model

Company DescriptionHeraMED Ltd. (HMD) is a healthcare technology company specializing in innovative maternal and fetal health solutions. The company operates within the digital health sector, offering advanced medical-grade devices and software platforms designed to enhance prenatal care. Its core products include the HeraBEAT, an FDA-approved fetal heart rate monitor, and the HeraCARE platform, which provides comprehensive telehealth services and remote monitoring solutions for expectant mothers and healthcare providers.
How the Company Makes MoneyHeraMED Ltd. generates revenue primarily through the sale of its medical devices and subscription-based services. The HeraBEAT monitor is sold directly to consumers and healthcare providers, providing a steady stream of product sales revenue. Additionally, the company offers the HeraCARE platform on a subscription basis, allowing healthcare providers to access remote monitoring and telehealth services, which generates recurring revenue. Significant partnerships with healthcare organizations and clinics further contribute to its earnings by expanding the company's market reach and facilitating the integration of its technology into existing healthcare systems.

HeraMED Ltd. Financial Statement Overview

Summary
HeraMED Ltd. faces financial challenges with declining revenues and persistent losses. The income statement shows a steep decline in revenue and negative profit margins, while the balance sheet highlights low leverage but poor return on equity. Cash flow analysis shows negative operating cash flow and reliance on external financing, indicating financial instability.
Income Statement
30
Negative
The income statement reveals a declining revenue trend, with a decrease from $402,897 in 2023 to $225,492 in 2024. Gross profit margin is 60%, indicating decent cost management relative to sales. However, the company is experiencing significant net losses, with a net profit margin of -150.76% in 2024, reflecting poor profitability and operational challenges. EBIT and EBITDA margins are also deeply negative, suggesting ongoing issues in core operations.
Balance Sheet
35
Negative
HeraMED Ltd. shows a debt-to-equity ratio of 0.03, indicating low leverage, which is beneficial for financial stability. However, the return on equity is -198.15%, signaling that the company is not generating returns on shareholders' investments. The equity ratio stands at 61.80%, demonstrating a solid equity base relative to total assets. Despite these positives, the company's financial stability is undermined by continuous losses.
Cash Flow
40
Negative
The cash flow analysis highlights a negative operating cash flow of $-2,979,762, consistent with the net income losses, but financing activities injected $4,257,070 in cash, providing temporary liquidity support. Free cash flow remains negative, and the free cash flow to net income ratio indicates a substantial cash burn relative to losses. The company's reliance on external financing poses potential risks if such funding becomes unavailable.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue225.49K402.90K
Gross Profit79.75K241.94K
EBITDA-3.35M-3.97M
Net Income-3.40M-4.50M
Balance Sheet
Total Assets2.78M2.01M
Cash, Cash Equivalents and Short-Term Investments1.96M723.29K
Total Debt815.96K209.37K
Total Liabilities1.06M1.55M
Stockholders Equity1.72M466.70K
Cash Flow
Free Cash Flow-2.98M-3.80M
Operating Cash Flow-2.98M-3.89M
Investing Cash Flow0.00-1.39K
Financing Cash Flow4.26M2.02M

HeraMED Ltd. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.01
Price Trends
50DMA
0.01
Negative
100DMA
0.02
Negative
200DMA
0.02
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
39.98
Neutral
STOCH
66.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:HMD, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.02, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 39.98 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:HMD.

HeraMED Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
AUTLX
69
Neutral
$8.19B160.2014.52%55.85%893.42%
AURHT
64
Neutral
AU$18.38M140.00-3.11%89.13%69.57%
AUPNV
58
Neutral
$804.83M135.478.30%39.19%273.91%
49
Neutral
AU$2.53B3.19-57.47%2.77%36.73%13.67%
AUCMP
48
Neutral
AU$49.98M-8.08%-5.62%-225.71%
AUIDT
47
Neutral
AU$41.35M-19.31%72.25%43.66%
AUHMD
45
Neutral
AU$9.63M-321.94%-39.97%55.29%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:HMD
HeraMED Ltd.
0.01
-0.01
-56.00%
AU:TLX
Telix Pharmaceuticals
24.04
6.49
36.98%
AU:CMP
Compumedics Limited
0.26
-0.08
-23.53%
AU:RHT
Resonance Health Ltd
0.04
-0.02
-33.33%
AU:PNV
Polynovo
1.14
-1.20
-51.29%
AU:IDT
IDT Australia Limited
0.10
>-0.01
-9.09%

HeraMED Ltd. Corporate Events

HeraMED Limited Schedules Annual General Meeting for May 2025
Apr 28, 2025

HeraMED Limited has announced the scheduling of its Annual General Meeting (AGM) for 29 May 2025, to be held at BDO Offices in Docklands, VIC. The company emphasizes the importance of shareholder participation, encouraging votes to be submitted by proxy if attendance is not possible. This meeting is significant for stakeholders as it will address resolutions affecting shareholding, with all resolutions to be decided by a poll.

HeraMED Limited Announces AGM Date and Director Nomination Deadline
Apr 7, 2025

HeraMED Limited has announced that its Annual General Meeting will take place on May 29, 2025, and has set April 14, 2025, as the deadline for director nominations. This announcement underscores the company’s ongoing governance activities and provides stakeholders with an opportunity to influence its strategic direction through board elections.

HeraMED to Showcase Innovations at NWR Virtual Healthcare Conference
Mar 18, 2025

HeraMED Limited announced its participation in the NWR Virtual Healthcare Conference, where CEO Anoushka Gungadin will present the company’s advancements in digital maternity care. This presentation underscores HeraMED’s commitment to revolutionizing the maternity care industry and highlights its strategic efforts to engage with stakeholders and investors, potentially enhancing its market position and influence in the healthcare sector.

HeraMED Ltd. Releases 2024 Corporate Governance Statement
Feb 28, 2025

HeraMED Ltd. has released its corporate governance statement for the financial year ending December 31, 2024, which has been approved by the board as of February 28, 2025. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, indicating that the company has followed these guidelines throughout the reporting period. This release underscores HeraMED’s commitment to transparency and accountability, potentially strengthening its position in the market and reassuring stakeholders of its governance practices.

HeraMED Ltd. Releases 2024 Annual Report Highlighting Strategic Growth
Feb 28, 2025

HeraMED Ltd. has released its annual report for the year ending December 31, 2024, highlighting its financial performance and strategic initiatives. The report provides insights into the company’s operations, including its commitment to expanding its market presence and improving shareholder value, which may influence its industry positioning and stakeholder interests.

HeraMED Ltd. Reports Revenue Decline and Improved Net Loss for 2024
Feb 28, 2025

HeraMED Ltd. reported a 20.6% decline in revenues for the year ending December 31, 2024, with a net loss of $5,490,578, marking a 19% improvement over the previous year’s loss. Despite the financial downturn, the company did not declare any dividends, and its net tangible assets per ordinary security increased to 0.23 cents, indicating a potential strengthening of its asset base.

HeraMED Partners with Garmin Health to Enhance Pregnancy Monitoring
Feb 24, 2025

HeraMED Limited has entered into a strategic collaboration with Garmin Health to integrate Garmin smartwatch data into its HeraCARE platform, enhancing remote pregnancy monitoring. This partnership will expand the range of health data available to expectant mothers, improve continuous monitoring capabilities, and support women’s health research. The collaboration is expected to enhance HeraMED’s industry positioning by providing a more holistic view of maternal health, aligning with its ‘data-as-an-asset’ strategy.

HeraMED Ltd. Pioneers Digital Transformation in Maternity Care
Feb 19, 2025

HeraMED Ltd. has released a presentation highlighting its commitment to leading the digital transformation of maternity care. The announcement underlines the company’s strategic positioning within the healthcare industry, showcasing its FDA-approved solutions aimed at enhancing maternity care services, which could potentially strengthen its market position and stakeholder confidence.

HeraMED Announces Director’s Acquisition of Performance Rights
Feb 17, 2025

HeraMED Ltd. has announced a change in the director’s interest, revealing that Anoushka Gungadin, a director of the company, has acquired 15,800,000 performance rights. These rights are tied to specific share price premiums and accumulated user metrics on the HeraCARE platform, which suggests a strategic focus on enhancing shareholder value and platform growth. This change could potentially impact HeraMED’s operational strategies and stakeholder interests by aligning director incentives with the company’s performance goals, thereby reinforcing its commitment to achieving key financial and user engagement targets.

HeraMED Ltd. Issues 15.8 Million Performance Rights in Employee Incentive Scheme
Feb 17, 2025

HeraMED Ltd. announced the issuance of 15,800,000 unquoted performance rights under an employee incentive scheme. These securities are designed to reward and retain staff, supporting the company’s growth and operational goals. The issuance is part of HeraMED’s strategic efforts to strengthen its workforce and maintain its competitive position in the healthcare technology market.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 01, 2025